Dana Inc
Auto Components
Dana Inc (DAN) Stock News
The latest DAN headlines and market coverage — 8 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
PERSONALIZATIONS AND MIX CONTINUE TO DRIVE STRONG RESULTS AND 2026 GUIDANCE RAISE
Ferrari N.V. announced Q2 2026 net revenues of €1,938 million (up 8% YoY), operating profit of €605 million with a 31.2% margin, and net profit of €463 million. The company raised its 2026 guidance citing stronger-than-expected personalizations and lower currency headwinds. The order book covers deliveries through 2027, with new model launches including the Ferrari Luce and 12Cilindri Manuale contributing to the company's most complete product lineup in history.
- GlobeNewswire Inc.·
DANONE : Notification de mise à disposition par Danone de son rapport financier semestriel 2026
Danone released its half-year financial report for 2026, reporting strong Q2 performance with sales up 4.2%. The company continues to execute its Renew strategy focused on health-oriented products across dairy, plant-based, water, and specialized nutrition categories. With nearly 90,000 employees and presence in over 120 countries, Danone maintains its position as a leading food company.
- GlobeNewswire Inc.·
DANONE : Forte performance au T2 et résultats solides au 1er semestre, reflétant la pertinence de notre portefeuille de produits axé sur la santé
Danone delivered solid first-half 2026 results with comparable revenue growth of 3.5% and Q2 growth of 4.2%, driven by strong performance across all geographic regions and product categories. The company maintained operating margin at 13.3% despite inflationary pressures through productivity gains, and confirmed 2026 guidance for 3-5% comparable revenue growth with faster operating result growth. Strategic acquisitions of Huel and Made Group strengthen the company's health-focused portfolio in key markets.
- GlobeNewswire Inc.·
Halper Sadeh LLC is Investigating Whether LCII, NUVL, DAN, TMHC are Obtaining Fair Deals for their Shareholders
Investor rights law firm Halper Sadeh LLC is investigating four major corporate transactions to determine if shareholders are receiving fair deals. The investigations cover LCI Industries' sale to Patrick Industries, Nuvalent's acquisition by GSK, Dana Incorporated's merger with Eaton Corporation, and Taylor Morrison's sale to Berkshire Hathaway. The firm is examining potential securities law violations and breaches of fiduciary duties, particularly regarding insider benefits and terms that may limit competing offers.
- GlobeNewswire Inc.·
Halper Sadeh LLC is Investigating Whether DAN, ROKU, TBRG, AFBI are Obtaining Fair Deals for their Shareholders
Investor rights law firm Halper Sadeh LLC is investigating four proposed mergers and acquisitions to determine if shareholders are receiving fair deals. The investigations focus on Dana Incorporated's sale to Eaton Corporation, Roku's acquisition by Fox Corporation, TruBridge's sale to Inventurus Knowledge Solutions, and Affinity Bancshares' merger with Fidelity BancShares. The firm is examining potential securities law violations and fiduciary duty breaches, particularly regarding insider benefits and terms that may limit competing offers.
- GlobeNewswire Inc.·
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Arcosa, Inc. (NYSE – ACA), Fathom Holdings Inc. (Nasdaq – FTHM), Nuvalent, Inc. (Nasdaq – NUVL), Dana Incorporated (NYSE – DAN)
Law firm Brodsky & Smith announced investigations into four major merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and provide fair value to shareholders. The investigations involve Arcosa (CRH acquisition for $150/share), Fathom Holdings (Bed Bath & Beyond acquisition), Nuvalent (GSK acquisition for $124/share), and Dana Incorporated (Eaton Corporation acquisition).
- Benzinga·
BURLINGTON STORES REPORTS STRONG FIRST QUARTER SALES AND EARNINGS GROWTH, WELL AHEAD OF GUIDANCE. THIS REPRESENTS THE 14TH CONSECUTIVE QUARTER OF DOUBLE DIGIT EPS GROWTH.
<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <ul> <li style="list-style-type:none;"> <ul> <li style="text-align:left;"><strong>Total sales increased 14%, on top of 6% last year </strong></li> <li style="text-align:left;"><strong>Comparable store sales increased 6%</strong></li> <li style="text-align:left;"><strong>Net income was $115 million, and diluted EPS was $1.79 </strong></li> <li style="text-align:left;"><strong>Excluding certain expenses associated with bankruptcy acquired leases: </strong> <ul> <li><strong>Adjusted EPS increased 26% to $2.10, well above guidance</strong></li> <li><strong>Full year adjusted EPS guidance is now $11.45 to $11.80<br /><br /></strong></li> </ul> </li> </ul> </li> </ul> <p align="left">BURLINGTON, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Burlington Stores, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/BURL" rel="nofollow">BURL</a>), a nationally recognized off-price retailer of high-quality, branded apparel, footwear, accessories, and merchandise for the home at everyday low prices, today announced its results for the first quarter ended May 2, 2026.</p> <p align="left">Michael O&#039;Sullivan, CEO, stated, "We are pleased with our strong performance in the first quarter. Adjusted EPS grew 26% versus the first quarter of last year, which represented our 14th consecutive quarter of double digit EPS growth. This track record demonstrates our ability to consistently convert sales into operati
- GlobeNewswire Inc.·
NANOBIOTIX ANNONCE LA PRÉSENTATION DE DONNÉES DE LA PREMIÉRE PARTIE DE L’ÉTUDE CLINIQUE RANDOMISÉE DE PHASE 2 EVALUANT JNJ-1900 (NBTXR3) DANS LES CANCERS DU POUMON DE STADE 3 INOPÉRABLE
Nanobiotix announced early results from the Phase 2 CONVERGE study evaluating JNJ-1900 (NBTXR3), a nanoradioenhancer developed in collaboration with Johnson & Johnson, in patients with stage 3 inoperable non-small cell lung cancer. The study showed promising efficacy with an 85.7% overall response rate and 57.1% complete response rate in 7 patients who completed treatment, compared to less than 5% complete response rates with current standard of care.